Introduction
============

Adiponectin of molecular mass 28 kDa is a member of the adipocytokines, and it is secreted exclusively by mature adipocytes.[@b1-ott-11-2519] Biologically speaking, adiponectin possesses a well-defined set of properties, including insulin sensitization, anti-inflammation, anti-atherosclerosis, proapoptosis and antiproliferation.[@b2-ott-11-2519],[@b3-ott-11-2519] In circulation, adiponectin exists in forms of trimer, hexamer and high-molecular weight (HMW) complex, and these fractions are proven to have different biological activities.[@b4-ott-11-2519] For example, HMW adiponectin has a close relationship to insulin sensitivity, while the relevance between non-HMW adiponectin and anti-inflammation is more obvious.[@b5-ott-11-2519] Mounting evidence from human studies reveal that low total adiponectin in circulation represents a predisposing status for development of colorectal cancer.[@b6-ott-11-2519]--[@b8-ott-11-2519] By contrast, other researchers failed to confirm this claim,[@b9-ott-11-2519]--[@b11-ott-11-2519] and some of them even found a higher concentration of circulating total adiponectin in patients with colorectal cancer than in controls.[@b12-ott-11-2519],[@b13-ott-11-2519] Several systematic reviews and meta-analyses have summarized published data involving the association between circulating total adiponectin and colorectal cancer risk,[@b14-ott-11-2519]--[@b20-ott-11-2519] while interpretation of pooled findings in most cases is clouded by the presence of substantial heterogeneity and none considered adiponectin fractions as separate factors. With growing epidemiological data, our understanding on circulating adiponectin and its fractions and colorectal cancer needs replenishment and renewal. Hence, the principal goal of the present study is to test the hypothesis that circulating total adiponectin or certain fractions may represent a promising biological candidate in modulating the risk of colorectal cancer, assessed through a comprehensive meta-analysis. A secondary goal is to explore possible sources of heterogeneity of effect size across studies through both subgroup analysis and meta-regression analysis.

Methods
=======

Guideline
---------

The present study was carried out in strict accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline.[@b21-ott-11-2519]

Paper identification
--------------------

Potentially eligible papers were identified through searching public databases of MEDLINE (PubMed), EMBASE, Web of Knowledge and Scholar (Google). All identified papers from each database were merged together and then duplicates removed. The key items used for paper identification included ("colorectal" or "colon" or "rectal") in title and ("cancer" or "carcinoma" or "tumor" or "tumour" or "neoplasm" or "adenoma") in title and ("adiponectin" or "adipocytokine" or "adipokine") in title/abstract. The process of paper identification was completed independently and in duplicate (Weiqun Lu and Zhiliang Huang) using the same key items mentioned above.

Eligibility criteria
--------------------

Eligibility criteria consisted of both inclusion criteria and exclusion criteria. Papers were included only when the following conditions were met simultaneously: (i) publication using the English language; (ii) either cross-sectional or nested case--control study design; (iii) involvement of only human beings; and (iv) availability of circulating plasma or serum adiponectin concentration for patients with colorectal or colon or rectal cancer and cancer-free controls. Papers were excluded when any of the following conditions was true: (i) non-original contribution; (ii) narrative or systematic review or meta-analysis; (iii) conference abstract; and (iv) case report or case series.

Paper selection
---------------

Two authors (Weiqun Lu and Zhiliang Huang) selected the papers that met the above inclusion criteria through reviewing the title or abstract or the full text, if necessary, of each identified article. When disagreement happened during the selection process, it was resolved by discussion or seeking help from the third author (Haiying Liu).

Data extraction
---------------

From each qualified paper, data for analysis including, if available, the first author's name, publication year, country where the study was conducted, study design, cancer subtype, matching status, source of controls, selection of controls, sample size, assay method for circulating adiponectin, sample type, age, gender, body mass index (BMI), waist--hip ratio (WHR), waist circumference, physical activity, physical inactivity, smoking habit, family history, diabetes mellitus, glucose, insulin, C-reactive protein (CRP) and adiponectin were extracted and entered into databases by two authors (Weiqun Lu and Zhiliang Huang). Extracted data were compared, and disagreement was resolved through consensus and discussion.

Statistical analysis
--------------------

Data were statistically analyzed by the Stata/SE software version 14.0 (StataCorp LP, College Station, TX, USA). Weighted mean difference (WMD) was adopted to assess the difference in circulating adiponectin concentration between patients and controls in both overall and subgroup analyses, and its 95% confidence interval (95% CI) was estimated accordingly under the random-effects model based on the DerSimonian--Laird method. Heterogeneity was first evaluated with the *I*^2^ statistic, and then was explored through both subgroup and meta-regression analyses. The *I*^2^ statistic is expressed as a percentage figure, and the higher the figure, the more likely the heterogeneity becomes. It is widely accepted the significance cutoff point of *I*^2^ statistic is set at 50%. Publication bias was assessed by the Begg's funnel plot, filled funnel plot and Egger's regression asymmetry test. The Egger's regression asymmetry test records significance if the probability value is \<10%.

Results
=======

Qualified studies
-----------------

A total of 339 papers were identified through searching public databases, and 295 of them were excluded after reading the title and abstract. Further, after full-text reviewing, 13 papers were excluded as they failed to meet our predefined inclusion criteria, leaving 31 eligible papers for meta-analysis in this study.[@b5-ott-11-2519]--[@b13-ott-11-2519],[@b22-ott-11-2519]--[@b43-ott-11-2519] Thereof, 16 papers provided data by cancer type, gender or race, and so there were 48 qualified studies.

Study characteristics
---------------------

[Table 1](#t1-ott-11-2519){ref-type="table"} shows the baseline characteristics of all qualified studies. After removing shared controls, this meta-analysis involved 7,554 patients with colorectal cancer and 9,798 controls. Of 48 qualified studies, only one study focused on HMW adiponectin.[@b39-ott-11-2519] In addition, eight studies also measured HMW adiponectin, and non-HMW adiponectin was recorded in six studies.

Overall analysis
----------------

Overall analysis was based on 41 qualified studies, and the funnel plot illustrating the difference in total adiponectin concentrations between patients with colorectal cancer and controls is presented in [Figure 1](#f1-ott-11-2519){ref-type="fig"}. Pooling effect size of all studies found that total adiponectin was significantly lower in patients with colorectal cancer than in controls (WMD: −0.76 µg/mL, 95% CI: −1.20 to −0.32, *p*=0.001). However, this significant finding was clouded by strong evidence of statistical heterogeneity (*I*^2^: 94.2%, *p*\<0.001).

[Figure 2](#f2-ott-11-2519){ref-type="fig"} shows another funnel plot quantifying the differences in adiponectin fractions -- HMW adiponectin and non-HMW adiponectin -- between patients with colorectal cancer and controls. The difference in HMW adiponectin was comparable between the two groups (WMD: −0.22 µg/mL, 95% CI: −0.70 to 0.25, *p*=0.350), with significant heterogeneity (*I*^2^: 97.3%, *p*\<0.001). By contrast, non-HMW adiponectin was significantly lower in patients with colorectal cancer than in controls (WMD: −0.27 µg/mL, 95% CI: −0.35 to −0.19, *p*\<0.001), with only marginal heterogeneity (*I*^2^: 52.3%, *p*=0.063).

Subgroup analysis
-----------------

[Table 2](#t2-ott-11-2519){ref-type="table"} summarizes the differences in total adiponectin between patients and controls by grouping studies according to cancer subtype, region, study design, matching status, sample source, gender, BMI, WHR and diabetes mellitus, respectively.

By cancer subtype, significant difference in total adiponectin was observed in patients with colorectal adenoma (CRA), colon cancer and rectum cancer, respectively, relative to controls (WMD: −0.892, −1.073 and −0.681 µg/mL, *p*=0.010), with significant heterogeneity (*I*^2^: 80.1%, 97.3% and 75.4%).

By geographic region, besides Middle East, total adiponectin was significantly lower in patients than in controls from America, Europe and especially East Asia (WMD: −1.707 µg/mL, *p*=0.008), and only in America, there was no evidence of heterogeneity (*I*^2^: 36.7%).

By study design, significant difference was observed only in nested case--control studies (WMD: −0.266 µg/mL, *p*\<0.001), without heterogeneity (*I*^2^: 12.4%).

By matching status, studies with matched patients and controls failed to identify any significance (WMD: −0.099 µg/mL, *p*=0.504) (*I*^2^: 79.0%), while in studies with unclear matching status, there was significant difference in total adiponectin between patients and controls (*I*^2^: 96.1%).

By sample source, total adiponectin was significantly and comparably reduced in studies collecting plasma and serum samples for adiponectin measurement (WMD: −0.714 and −0.803 µg/mL, *p*=0.030 and 0.012, *I*^2^: 95.1% and 93.3%, respectively).

By sample size, grouping studies by median total sample size showed that the reduction of total adiponectin was obvious in studies with total sample size \>230 (WMD: −0.271 µg/mL, *p*\<0.001), and the likelihood of heterogeneity was low (*I*^2^: 12.1%).

By gender, total adiponectin was reduced significantly in male patients relative to male controls (WMD: −0.671 µg/mL, *p*=0.025) (*I*^2^: 90.4%), and there was no observable significance in females.

By obesity, studies were grouped by mean or median BMI at 25 kg/m^2^, and significant reduction in total adiponectin was noted in both groups, especially in studies with BMI \<25 kg/m^2^ (WMD: −1.627 µg/mL, *p*=0.029) (*I*^2^: 92.1%). In addition, when studies were grouped by mean or median WHR at 0.9 m, there was significant reduction in studies with WHR ≥0.9 m (WMD: −0.522 µg/mL, *p*=0.014).

After restricting to studies involving subjects free of diabetes mellitus, the reduction in total adiponectin was not statistically significant, and there was significant heterogeneity.

By tumor node metastasis stage, the reduction in magnitude of total adiponectin was slightly stronger in patients with stage I--II colorectal cancer (WMD: −1.280 µg/mL, *p*=0.003) than in patients with stage III--IV cancer (WMD: −1.196 µg/mL, *p*=0.005), and significance was detected in both subgroups with significant heterogeneity but a low probability of publication bias.

Meta-regression analysis
------------------------

[Table 3](#t3-ott-11-2519){ref-type="table"} lists the results of meta-regression analysis by incorporating all characteristics to assess whether they can explain the heterogeneity between total adiponectin and colorectal cancer. Age and smoking in both patients and controls were significant potential sources of heterogeneity, and BMI, waist circumference and CRP can account for heterogeneity only in patients (*p*\<0.05).

Publication bias
----------------

Overall comparison of total adiponectin between patients with colorectal cancer and controls was not subject to publication bias, which was illustrated by both Begg's and filled funnel plots in [Figure 3](#f3-ott-11-2519){ref-type="fig"}, as well as by the Egger's regression asymmetry test (*p*=0.336). For comparisons in subgroup analysis, there was consistently low likelihood of publication bias across all subgroups (Egger's test, *p*\<0.1), as presented in [Table 2](#t2-ott-11-2519){ref-type="table"}.

Discussion
==========

The most noteworthy finding of this present study is that in line with the conclusions of most previous studies,[@b14-ott-11-2519]--[@b20-ott-11-2519] our data indicated that low total adiponectin in circulation was a significant risk factor for colorectal cancer. Moreover, for the first time, we pooled data according to adiponectin fractions and found that only non-HMW adiponectin differed significantly between patients with colorectal cancer and controls. We further identified age, gender, smoking, obesity, study design, matching status and sample size as potential sources of heterogeneity. To our knowledge, this is thus far the largest meta-analysis dealing with the relationship of circulating adiponectin and its fractions with colorectal cancer.

The connection between obesity and colorectal cancer is well established,[@b44-ott-11-2519],[@b45-ott-11-2519] and a great deal of supporting evidence from clinical and epidemiological data has suggested that this connection is probably mediated by abnormal adiponectin in circulation.[@b46-ott-11-2519] Adiponectin is the most abundant hormone secreted by adipose tissue, and its anti-inflammatory and insulin-sensitizing properties may, at least in part, expound on the etiologic link between obesity and colorectal cancer.[@b47-ott-11-2519],[@b48-ott-11-2519] Moreover, accumulating evidence has highlighted a contributory role of adiponectin in anti-carcinogenesis.[@b49-ott-11-2519],[@b50-ott-11-2519] In vitro studies have showed that adiponectin can promote endothelial apoptosis, repress the maturation and proliferation of colorectal cancer cells and control colony formation, likely through the activation of AMPK-mTOR signaling pathway.[@b39-ott-11-2519],[@b51-ott-11-2519],[@b52-ott-11-2519] Based on the above evidence, it is more reasonable to presume that circulating adiponectin may be involved in the pathophysiological process of colorectal cancer.

Consistent with the findings of major published studies,[@b14-ott-11-2519]--[@b20-ott-11-2519] we confirmed in this present study that low total adiponectin in circulation was a significant risk factor for colorectal cancer. As with most previous meta-analyses, heterogeneity is a serious issue that limits interpretation of effect estimates and requires careful exploration.[@b53-ott-11-2519] As a secondary goal of this study, we employed both subgroup analysis and meta-regression analysis to seek possible causes of heterogeneity between studies. In particular, the reduction in total adiponectin was more obvious for CRA and colon cancer, and in studies enrolling subjects of male gender, from East Asia and with normal weight. In addition, the association of total adiponectin with colorectal cancer was markedly significant in studies with a nested case--control design and a large sample size, relative to studies with a retrospective case--control design and a small sample size, indicating the robustness of our observation. Colorectal cancer is a highly heterogeneous disease to which environmental exposure, germ-line susceptibility determinants and accumulated genetic and epigenetic changes contribute interactively.[@b54-ott-11-2519] For example, cigarette smoking and alcohol drinking, which are more prevalent in men than in women, are established risk factors for the development and progression of colorectal gender-specific difference in adiponectin observed in the present study. Nevertheless, even though we have made great endeavors to seek causes of heterogeneity, there is still strong evidence of heterogeneity in some subgroups, indicating that residual confounding from other sources of heterogeneity in colorectal cancer risk is likely. We agree that further explorations are necessary, and especially analysis of individual participant data could yield further insights.

However, a growing body of research has reported diverse biological activities of different adiponectin fractions, mainly focusing on HMW (insulin sensitivity) and non-HMW (inflammation response) forms.[@b5-ott-11-2519],[@b24-ott-11-2519] In this context, the sufficient number of eligible studies in this meta-analysis enables us to investigate different adiponectin fractions, and our findings revealed that low non-HMW adiponectin in circulation was a significant risk factor for colorectal cancer and there was no observable significant difference for HMW adiponectin. As previously discussed, non-HMW adiponectin plays a major role in the inflammatory process.[@b24-ott-11-2519] Systemic inflammation is a key manifestation of cancer progression and metastasis in many types of cancer including colorectal cancer.[@b57-ott-11-2519] We thus develop a further presumption that non-HMW adiponectin may be involved in colorectal carcinogenesis by regulating inflammatory responses. Addressing this presumption is beyond the scope of this meta-analysis, and further experimental studies are required.

Finally, the present study needs to be interpreted cautiously, bearing in mind the following limitations. First, we only retrieved the literature for the papers published in English language, and selection bias cannot be ruled out. Second, all involved studies in this meta-analysis were observational in nature, either cross-sectional or nested, which hindered further causality inference. Third, as discussed above, sources of heterogeneity for a majority of comparisons were not fully accounted for, and additional considerations were necessary. For example, low circulating adiponectin was found to be associated with *KRAS*-mutant colorectal cancer risk but not with *KRAS*-wild-type cancer risk.[@b29-ott-11-2519] Fourth, only data on circulating plasma/serum adiponectin were summa-rized, and it is expected that tissue adiponectin concentration in tumor environment may be more relevant to the evaluation of colorectal cancer risk than its circulating concentration. However, data on tissue adiponectin are rarely reported. Fifth, circulating adiponectin concentration was affected by medical treatment or drug intervention, which cannot be taken into account because of lack of data.

In conclusion, through a comprehensive meta-analysis of 7,554 patients with colorectal cancer and 9,798 controls, our data indicate that low total adiponectin, especially its non-HMW fraction, represents a promising risk factor for colorectal cancer. Although there is still residual confounding unaccounted for, we believe that this study can aid in better understanding cancer heterogeneity, highlighting the importance of anti-inflammation therapies to prevent or delay the occurrence of colorectal cancer and thereby providing new insight in its physiology. In addition, further studies are needed to explore underlying mechanisms.
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**Note:** Weights are from random-effects analysis.\
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###### 

The baseline characteristics of all qualified studies

  Study                                                 Year   Region        Cancer subtype   Control features     Study design    Matching status   ADI assay (ELISA)   Sample size   Sample source   Adiponectin (µg/mL)   Age (years)   Male gender   BMI (kg/m^2^)                                 
  ----------------------------------------------------- ------ ------------- ---------------- -------------------- --------------- ----------------- ------------------- ------------- --------------- --------------------- ------------- ------------- --------------- ------ ------- ------- ------ ------
  Saetang et al[@b25-ott-11-2519] (CRC)                 2016   East Asia     CRC              W/o colonic polyps   Retrospective   NA                Thermo Fisher       82            30              Serum                 17.56         19.49         62.4            59.1   NA      NA      NA     NA
  Saetang et al[@b25-ott-11-2519] (colon)               2016   East Asia     Colon            W/o colonic polyps   Retrospective   NA                Thermo Fisher       52            30              Serum                 15.65         19.49         62.4            59.1   NA      NA      NA     NA
  Saetang et al[@b25-ott-11-2519] (rectum)              2016   East Asia     Rectum           W/o colonic polyps   Retrospective   NA                Thermo Fisher       30            30              Serum                 20.49         19.49         62.4            59.1   NA      NA      NA     NA
  Inamura et al[@b29-ott-11-2519] (HPFS)                2016   USA           CRC              W/o CRC              Nested          Yes               ALPCO               155           296             Plasma                5.00          5.60          66.2            66.2   1.000   1.000   26.1   25.3
  Inamura et al[@b29-ott-11-2519] (NHS)                 2016   USA           CRC              W/o CRC              Nested          Yes               ALPCO               152           297             Plasma                7.90          8.20          58.5            66.2   0.000   0.000   25.2   24.7
  Zekri et al[@b13-ott-11-2519]                         2015   Middle East   CRC              W/o CRC              Retrospective   NA                RayBiotech          34            29              Serum                 11.28         6.59          41.3            66.2   0.588   0.552   NA     NA
  Demir et al[@b37-ott-11-2519]                         2015   Middle East   CRA              W/o CRC              Retrospective   NA                eBioscience         32            30              Serum                 8.57          9.70          53.5            66.2   0.625   0.500   29.1   26.1
  Chandler et al[@b11-ott-11-2519]                      2015   USA           CRC              W/o CRC              Nested          Yes               ALPCO               275           275             Plasma                6.00          6.24          58.8            66.2   0.000   0.000   26.8   26.3
  Ochs-Balcom et al[@b26-ott-11-2519] (white)           2014   USA           CRA              W/o CRA              Nested          NA                R&D                 217           650             Plasma                10.58         11.64         57.4            66.2   0.521   0.369   29.1   32.3
  Ochs-Balcom et al[@b26-ott-11-2519] (AA)              2014   USA           CRA              W/o CRA              Nested          NA                R&D                 175           378             Plasma                7.76          8.02          58.2            66.2   0.406   0.241   31.7   32.3
  Aleksandrova et al[@b5-ott-11-2519] (colon)           2014   Europe        Colon            W/o CRC              Nested          Yes               ALPCO               794           794             Serum                 6.70          6.80          58.6            66.2   0.530   0.530   26.8   26.3
  Aleksandrova et al[@b5-ott-11-2519] (rectum)          2014   Europe        Rectum           W/o CRC              Nested          Yes               ALPCO               466           466             Serum                 6.50          6.80          58.0            66.2   0.457   0.457   26.6   26.4
  Aleksandrova et al[@b40-ott-11-2519] (men)            2014   Europe        Colon            W/o CRC              Nested          Yes               ALPCO               292           292             Serum                 5.40          5.30          59.3            66.2   1.000   1.000   27.3   26.5
  Aleksandrova et al[@b40-ott-11-2519] (women)          2014   Europe        Colon            W/o CRC              Nested          Yes               ALPCO               370           370             Serum                 8.30          8.40          58.6            66.2   0.000   0.000   26.4   26.1
  Abe Vicente et al[@b43-ott-11-2519]                   2014   USA           CRC              Healthy              Retrospective   NA                R&D                 39            40              Serum                 4.60          3.60          61.0            66.2   0.590   0.650   23.9   23.9
  Song et al[@b24-ott-11-2519] (men)                    2013   USA           CRC              W/o CRC              Nested          Yes               Linco               270           519             Plasma                4.99          5.32          65.8            66.2   1.000   1.000   26.2   25.4
  Song et al[@b24-ott-11-2519] (women)                  2013   USA           CRC              W/o CRC              Nested          Yes               Linco               346           686             Plasma                8.04          8.19          59.0            66.2   0.000   0.000   26.0   25.5
  Danese et al[@b38-ott-11-2519] (men)                  2013   Europe        CRA              W/o CRC              Retrospective   Yes               Mediagnost          21            26              Plasma                7.86          5.83          63.0            66.2   0.525   0.650   26.0   26.0
  Danese et al[@b38-ott-11-2519] (women)                2013   Europe        CRA              W/o CRC              Retrospective   Yes               Mediagnost          19            14              Plasma                11.81         9.89          NA              NA     NA      NA      NA     NA
  Kemik et al[@b8-ott-11-2519] (colon)                  2012   Middle East   Colon            Healthy              Retrospective   NA                Linco               32            40              Serum                 4.80          6.50          49.5            40.4   0.563   0.550   15.9   21.5
  Kemik et al[@b8-ott-11-2519] (rectum)                 2012   Middle East   Rectum           Healthy              Retrospective   NA                Linco               35            40              Serum                 4.70          6.50          44.8            40.4   0.543   0.550   16.2   21.5
  Ho et al[@b30-ott-11-2519]                            2012   USA           CRC              W/o CRC              Nested          NA                Millipore           457           834             Plasma                27.20         29.10         NA              NA     NA      NA      NA     NA
  Hillenbrand et al[@b31-ott-11-2519] (men)             2012   Europe        CRC              Healthy              Retrospective   NA                Millipore           42            30              Serum                 14.20         11.80         65.5            46.0   1.000   1.000   27.2   NA
  Hillenbrand et al[@b31-ott-11-2519] (women)           2012   Europe        CRC              Healthy              Retrospective   NA                Millipore           25            30              Serum                 21.90         22.50         66.0            44.0   0.000   0.000   26.4   NA
  Gulcelik et al[@b32-ott-11-2519]                      2012   Middle East   Colon            W/o cancer           Retrospective   NA                B-Bridge            27            40              Serum                 9.51          13.91         52.1            52.4   0.593   0.250   26.8   26.8
  Chen et al[@b39-ott-11-2519] (E)                      2012   East Asia     CRC              W/o colonic polyps   Retrospective   NA                Adlitteram          71            102             Plasma                10.10         13.20         62.1            58.3   1.000   1.000   23.5   22.9
  Chen et al[@b39-ott-11-2519] (A)                      2012   East Asia     CRC              W/o colonic polyps   Retrospective   NA                Adlitteram          94            102             Plasma                9.30          13.20         61.8            58.3   1.000   1.000   22.4   22.9
  Aleksandrova et al[@b41-ott-11-2519] (colon)          2012   Europe        Colon            W/o CRC              Nested          Yes               ALPCO               755           755             Serum                 6.71          6.84          58.6            58.6   0.542   0.542   26.9   26.3
  Aleksandrova et al[@b41-ott-11-2519] (rectum)         2012   Europe        Rectum           W/o CRC              Nested          Yes               ALPCO               451           451             Serum                 6.38          6.79          58.0            58.0   0.452   0.452   26.5   26.4
  Al-Harithy and Al-Zahrani[@b42-ott-11-2519] (men)     2012   Middle East   CRC              Healthy              Retrospective   Yes               ALPCO               31            30              Serum                 5.59          6.38          55.0            49.0   1.000   1.000   24.8   29.1
  Al-Harithy and Al-Zahrani[@b42-ott-11-2519] (women)   2012   Middle East   CRC              Healthy              Retrospective   Yes               ALPCO               29            30              Serum                 4.47          8.89          53.5            52.0   0.000   0.000   26.8   28.8
  Gialamas et al[@b34-ott-11-2519]                      2011   Europe        CRC              Healthy              Retrospective   Yes               RI                  104           208             Serum                 9.45          10.38         69.8            69.1   0.625   0.625   NA     NA
  Chronis et al[@b10-ott-11-2519] (NOAA)                2011   Europe        CRA              W/o CRA              Retrospective   NA                Linco               22            138             Serum                 10.90         10.20         65.1            63.5   0.545   0.587   26.4   27.4
  Chronis et al[@b10-ott-11-2519] (AA)                  2011   Europe        CRA              W/o CRA              Retrospective   NA                Linco               46            138             Serum                 11.20         10.20         66.2            63.5   0.565   0.587   27.1   27.4
  Catalan et al[@b7-ott-11-2519]                        2011   Europe        Colon            Healthy              Retrospective   NA                R&D                 11            18              Plasma                4.07          8.09          66.0            44.0   NA      NA      26.9   29.3
  Al Khaldi et al[@b12-ott-11-2519]                     2011   Middle East   Colon            Healthy              Retrospective   Yes               Linco               58            68              Plasma                8.60          4.10          53.0            60.0   0.500   0.500   27.9   26.0
  Yamaji et al[@b22-ott-11-2519] (men)                  2010   East Asia     CRA              W/o CRA              Nested          NA                NA                  523           480             Plasma                3.98          4.37          NA              NA     1.000   1.000   NA     NA
  Yamaji et al[@b22-ott-11-2519] (women)                2010   East Asia     CRA              W/o CRA              Nested          NA                NA                  255           255             Plasma                6.81          7.36          NA              NA     0.000   0.000   NA     NA
  Nakajima et al[@b27-ott-11-2519]                      2010   East Asia     CRA              W/o CRC              Retrospective   Yes               Otsuka              115           115             Serum                 8.90          8.90          63.7            63.5   0.600   0.600   22.9   23.1
  Kemik et al[@b28-ott-11-2519]                         2010   Middle East   Colon            Healthy              Retrospective   NA                Linco               126           36              Serum                 4.30          6.50          43.5            40.4   0.421   0.444   NA     NA
  Gonullu et al[@b33-ott-11-2519]                       2010   Middle East   CRC              Healthy              Retrospective   NA                Bio-Source          36            37              Serum                 5.50          6.20          56.6            51.0   0.500   0.541   27.2   27.0
  Erarslan et al[@b36-ott-11-2519] (CRA)                2009   Middle East   CRA              W/o colonic polyps   Retrospective   NA                RayBiotech          31            50              Serum                 7.40          9.20          63.0            59.0   0.548   0.540   26.0   29.2
  Erarslan et al[@b36-ott-11-2519] (CRC)                2009   Middle East   CRC              W/o colonic polyps   Retrospective   NA                RayBiotech          23            50              Serum                 7.10          9.20          57.0            59.0   0.609   0.540   24.6   29.2
  Stocks et al[@b9-ott-11-2519] (men)                   2008   Europe        CRC              W/o cancer           Nested          Yes               R&D                 125           245             Plasma                7.00          6.60          59.8            NA     1.000   1.000   NA     NA
  Stocks et al[@b9-ott-11-2519] (women)                 2008   Europe        CRC              W/o cancer           Nested          Yes               R&D                 181           350             Plasma                11.40         11.40         59.7            NA     0.000   0.000   NA     NA
  Ferroni et al[@b35-ott-11-2519]                       2007   Europe        CRC              W/o CRC              Retrospective   NA                BioVendor           60            35              Serum                 8.30          13.10         64.0            63.0   0.517   0.514   NA     NA
  Wei et al[@b23-ott-11-2519]                           2005   USA           CRC              W/o CRC              Nested          Yes               Linco               179           177             Plasma                7.40          7.80          66.6            66.5   1.000   1.000   25.9   25.4
  Otake et al[@b6-ott-11-2519]                          2005   East Asia     CRA              W/o colonic polyps   Retrospective   NA                Otsuka              51            52              Plasma                7.00          10.60         59.0            58.0   0.686   0.654   23.6   22.8

  Study                                                 Year   WHR    WC (cm)   DM      Physical activity (h/week)   Physical inactivity   Smoking   Family history   Glucose (mmol/L)   Insulin (µ U/mL)   CRP (mg/L)                                                                         
  ----------------------------------------------------- ------ ------ --------- ------- ---------------------------- --------------------- --------- ---------------- ------------------ ------------------ ------------ ------- ------- ------- ------- ------ ------ ------- ------- ------- ------
  Saetang et al[@b25-ott-11-2519] (CRC)                 2016   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Saetang et al[@b25-ott-11-2519] (colon)               2016   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Saetang et al[@b25-ott-11-2519] (rectum)              2016   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Inamura et al[@b29-ott-11-2519] (HPFS)                2016   NA     NA        NA      NA                           NA                    NA        32.1             30.4               NA                 NA           0.610   0.550   0.790   0.860   NA     NA     NA      NA      NA      NA
  Inamura et al[@b29-ott-11-2519] (NHS)                 2016   NA     NA        NA      NA                           NA                    NA        15.2             14.8               NA                 NA           0.560   0.510   0.840   0.850   NA     NA     NA      NA      NA      NA
  Zekri et al[@b13-ott-11-2519]                         2015   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Demir et al[@b37-ott-11-2519]                         2015   NA     NA        102.8   95.0                         0.000                 0.000     NA               NA                 NA                 NA           NA      NA      NA      NA      5.48   5.47   12.05   6.93    NA      NA
  Chandler et al[@b11-ott-11-2519]                      2015   NA     NA        NA      NA                           NA                    NA        15.4             16.5               NA                 NA           0.098   0.113   0.120   0.098   NA     NA     NA      NA      NA      NA
  Ochs-Balcom et al[@b26-ott-11-2519] (white)           2014   0.92   0.90      99.6    95.1                         0.078                 0.086     NA               NA                 NA                 NA           0.553   0.489   0.267   0.246   4.79   4.73   7.70    6.20    3.00    2.30
  Ochs-Balcom et al[@b26-ott-11-2519] (AA)              2014   0.97   0.93      105.0   104.1                        0.252                 0.226     NA               NA                 NA                 NA           0.703   0.608   0.166   0.238   5.55   5.22   15.30   9.90    2.40    2.30
  Aleksandrova et al[@b5-ott-11-2519] (colon)           2014   NA     NA        90.7    88.5                         NA                    NA        NA               NA                 0.152              0.116        0.237   0.215   NA      NA      NA     NA     NA      NA      NA      NA
  Aleksandrova et al[@b5-ott-11-2519] (rectum)          2014   NA     NA        90.4    89.7                         NA                    NA        NA               NA                 0.146              0.133        0.281   0.288   NA      NA      NA     NA     NA      NA      NA      NA
  Aleksandrova et al[@b40-ott-11-2519] (men)            2014   0.96   0.94      97.8    94.8                         NA                    NA        NA               NA                 0.178              0.147        0.281   0.253   NA      NA      NA     NA     NA      NA      2.80    1.90
  Aleksandrova et al[@b40-ott-11-2519] (women)          2014   0.81   0.81      84.3    82.6                         NA                    NA        NA               NA                 0.127              0.097        0.200   0.170   NA      NA      NA     NA     NA      NA      3.30    2.70
  Abe Vicente et al[@b43-ott-11-2519]                   2014   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Song et al[@b24-ott-11-2519] (men)                    2013   0.96   0.94      98.0    95.3                         NA                    NA        31.9             31.0               NA                 NA           0.050   0.049   0.196   0.139   NA     NA     NA      NA      1.34    1.13
  Song et al[@b24-ott-11-2519] (women)                  2013   0.79   0.78      81.0    79.5                         NA                    NA        16.6             16.9               NA                 NA           0.145   0.123   0.139   0.120   NA     NA     NA      NA      1.52    1.67
  Danese et al[@b38-ott-11-2519] (men)                  2013   NA     NA        97.5    95.9                         NA                    NA        NA               NA                 NA                 0.294        NA      NA      NA      NA      5.53   5.38   NA      NA      1.90    1.80
  Danese et al[@b38-ott-11-2519] (women)                2013   NA     NA        94.2    81.1                         NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Kemik et al[@b8-ott-11-2519] (colon)                  2012   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      9.10    3.50
  Kemik et al[@b8-ott-11-2519] (rectum)                 2012   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      9.10    3.50
  Ho et al[@b30-ott-11-2519]                            2012   NA     NA        NA      NA                           0.000                 0.000     NA               NA                 0.296              0.294        0.540   0.458   0.182   0.155   NA     NA     6.50    5.30    NA      NA
  Hillenbrand et al[@b31-ott-11-2519] (men)             2012   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Hillenbrand et al[@b31-ott-11-2519] (women)           2012   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Gulcelik et al[@b32-ott-11-2519]                      2012   NA     NA        NA      NA                           0.000                 0.000     NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Chen et al[@b39-ott-11-2519] (E)                      2012   0.89   0.86      NA      NA                           0.000                 0.000     NA               NA                 0.690              0.725        0.380   0.304   NA      NA      NA     NA     NA      NA      NA      NA
  Chen et al[@b39-ott-11-2519] (A)                      2012   0.85   0.86      NA      NA                           0.000                 0.000     NA               NA                 0.777              0.725        0.415   0.304   NA      NA      NA     NA     NA      NA      NA      NA
  Aleksandrova et al[@b41-ott-11-2519] (colon)          2012   0.88   0.87      90.4    88.1                         NA                    NA        NA               NA                 0.144              0.114        0.567   0.538   NA      NA      NA     NA     NA      NA      3.10    2.30
  Aleksandrova et al[@b41-ott-11-2519] (rectum)         2012   0.89   0.88      90.4    89.9                         NA                    NA        NA               NA                 0.151              0.131        0.609   0.603   NA      NA      NA     NA     NA      NA      2.40    2.30
  Al-Harithy and Al-Zahrani[@b42-ott-11-2519] (men)     2012   1.23   0.95      72.6    75.7                         NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Al-Harithy and Al-Zahrani[@b42-ott-11-2519] (women)   2012   0.95   1.01      61.0    84.6                         NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Gialamas et al[@b34-ott-11-2519]                      2011   1.01   0.94      NA      NA                           0.279                 0.173     NA               NA                 0.279              0.178        0.490   0.519   NA      NA      NA     NA     NA      NA      NA      NA
  Chronis et al[@b10-ott-11-2519] (NOAA)                2011   NA     NA        99.3    99.9                         0.000                 0.000     NA               NA                 NA                 NA           0.318   0.304   NA      NA      5.34   5.58   5.80    5.90    NA      NA
  Chronis et al[@b10-ott-11-2519] (AA)                  2011   NA     NA        99.2    99.9                         0.000                 0.000     NA               NA                 NA                 NA           0.261   0.304   NA      NA      5.70   5.58   7.10    5.90    NA      NA
  Catalan et al[@b7-ott-11-2519]                        2011   NA     NA        NA      NA                           0.000                 0.000     NA               NA                 NA                 NA           NA      NA      NA      NA      6.06   5.50   3.80    12.00   11.96   4.31
  Al Khaldi et al[@b12-ott-11-2519]                     2011   NA     NA        106.0   102.5                        0.000                 0.000     NA               NA                 NA                 NA           NA      NA      NA      NA      7.30   5.80   10.40   11.00   NA      NA
  Yamaji et al[@b22-ott-11-2519] (men)                  2010   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           0.138   0.135   NA      NA      NA     NA     NA      NA      NA      NA
  Yamaji et al[@b22-ott-11-2519] (women)                2010   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           0.216   0.102   NA      NA      NA     NA     NA      NA      NA      NA
  Nakajima et al[@b27-ott-11-2519]                      2010   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Kemik et al[@b28-ott-11-2519]                         2010   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      9.80    3.50
  Gonullu et al[@b33-ott-11-2519]                       2010   0.92   0.93      NA      NA                           0.000                 0.000     NA               NA                 NA                 NA           NA      NA      NA      NA      5.33   5.15   10.50   6.10    NA      NA
  Erarslan et al[@b36-ott-11-2519] (CRA)                2009   NA     NA        94.0    102.0                        0.000                 0.000     NA               NA                 NA                 NA           NA      NA      NA      NA      5.34   5.24   8.60    12.90   NA      NA
  Erarslan et al[@b36-ott-11-2519] (CRC)                2009   NA     NA        84.0    102.0                        0.000                 0.000     NA               NA                 NA                 NA           NA      NA      NA      NA      5.12   5.24   9.70    12.90   NA      NA
  Stocks et al[@b9-ott-11-2519] (men)                   2008   NA     NA        NA      NA                           0.000                 0.000     NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Stocks et al[@b9-ott-11-2519] (women)                 2008   NA     NA        NA      NA                           0.000                 0.000     NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Ferroni et al[@b35-ott-11-2519]                       2007   NA     NA        NA      NA                           NA                    NA        NA               NA                 NA                 NA           NA      NA      NA      NA      NA     NA     NA      NA      NA      NA
  Wei et al[@b23-ott-11-2519]                           2005   0.95   0.94      97.0    95.0                         NA                    NA        28.6             28.9               NA                 NA           0.051   0.054   0.207   0.126   NA     NA     NA      NA      NA      NA
  Otake et al[@b6-ott-11-2519]                          2005   NA     NA        NA      NA                           0.000                 0.000     NA               NA                 NA                 NA           NA      NA      NA      NA      5.83   5.11   8.50    6.10    NA      NA

**Abbreviations:** ADI, adiponectin; ELISA, enzyme-linked immunosorbent assay; CRC, colorectal cancer; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; CRA, colorectal adenoma; AA, advanced adenoma; NOAA, without advanced adenoma; W/o, without; BMI, body mass index; WHR, waist--hip ratio; WC, waist circumference; DM, diabetes mellitus; CRP, C-reactive protein; NA, not available.

###### 

Subgroup analysis of the difference in circulating adiponectin between patients with colorectal cancer and controls

  Characteristics        Subgroups       Studies (number)   WMD      95% CI             *p*^D^    *I*^2^   *p*^H^    *p*^E^
  ---------------------- --------------- ------------------ -------- ------------------ --------- -------- --------- --------
  Cancer subtype         CRC             20                 −0.736   −1.519 to 0.047    0.065     94.0%    \<0.001   0.514
                         CRA             10                 −0.892   −1.573 to −0.211   0.010     80.1%    \<0.001   0.473
                         Colon           10                 −1.073   −2.095 to −0.050   0.040     97.3%    \<0.001   0.403
                         Rectum          4                  −0.681   −1.358 to −0.005   0.048     75.4%    0.007     0.778
  Region                 East Asia       6                  −1.707   −2.979 to −0.436   0.008     95.1%    \<0.001   0.213
                         America         10                 −0.343   −0.599 to −0.087   0.009     36.7%    0.115     0.683
                         Europe          15                 −0.749   −1.451 to −0.047   0.037     94.3%    \<0.001   0.541
                         Middle East     10                 −0.787   −3.015 to 1.442    0.489     97.1%    \<0.001   0.787
  Study design           Retrospective   22                 −1.179   −2.536 to 0.177    0.088     96.2%    \<0.001   0.489
                         Nested          19                 −0.266   −0.380 to −0.152   \<0.001   12.4%    0.303     0.409
  Matching status        NA              21                 −1.472   −2.452 to −0.491   0.003     96.1%    \<0.001   0.411
                         Yes             20                 −0.099   −0.389 to 0.191    0.504     79.0%    \<0.001   0.693
  Sample source          Plasma          18                 −0.714   −1.358 to −0.070   0.030     95.1%    \<0.001   0.783
                         Serum           23                 −0.803   −1.430 to −0.176   0.012     93.3%    \<0.001   0.303
  Sample size (median)   ≤230            21                 −1.189   −2.609 to 0.231    0.101     96.4%    \<0.001   0.511
                         \>230           20                 −0.271   −0.385 to −0.157   \<0.001   12.1%    0.304     0.262
  Gender                 Men             9                  −0.671   −1.255 to −0.086   0.025     90.4%    \<0.001   0.536
                         Women           8                  −0.329   −0.693 to 0.035    0.077     49.6%    \<0.001   0.206
  BMI                    \<25 kg/m^2^    7                  −1.627   −3.092 to −0.163   0.029     92.1%    \<0.001   0.434
                         ≥25 kg/m^2^     24                 −0.527   −1.016 to −0.039   0.034     92.4%    \<0.001   0.611
  WHR                    \<0.9 m         5                  −0.878   −1.798 to 0.043    0.062     94.7%    \<0.001   0.112
                         ≥0.9 m          9                  −0.522   −0.939 to −0.106   0.014     60.6%    0.009     0.496
  DM                     Without         12                 −1.385   −3.003 to 0.233    0.093     96.1%    \<0.001   0.349
  TNM stage              I--II           9                  −1.280   −2.115 to −0.446   0.003     90.1%    \<0.001   0.103
                         III--IV         9                  −1.196   −2.033 to −0.358   0.005     92.6%    \<0.001   0.219

**Notes:** *p*^D^, the *p*-value for WMD; *I*^2^, inconsistency index; *p*^H^, the *p*-value for heterogeneity; *p*^E^, the *p*-value for Egger's regression asymmetry test.

**Abbreviations:** WMD, weighted mean difference; CI, confidence interval; CRC, colorectal cancer; CRA, colorectal adenoma; BMI, body mass index; WHR, waist--hip ratio; DM, diabetes mellitus; TNM, tumor node metastasis; NA, not available.

###### 

The meta-regression analysis of all characteristics in both patients with colorectal cancer and controls

  Characteristics       Studies (number)   Patients   Controls            
  --------------------- ------------------ ---------- ---------- -------- -------
  Age                   36                 −0.21      0.012      0.18     0.019
  Gender                38                 −8.45      0.076      8.37     0.073
  BMI                   29                 0.41       0.039      −0.35    0.091
  WHR                   14                 5.04       0.387      −10.47   0.282
  WC                    19                 0.14       0.008      −0.09    0.177
  DM                    15                 −3.71      0.913      8.86     0.840
  Physical activity     6                  −0.05      0.785      0.04     0.842
  Physical inactivity   9                  1.46       0.836      −7.74    0.315
  Smoking               20                 −10.59     0.032      10.59    0.043
  Family history        9                  −0.66      0.842      0.34     0.909
  Glucose               10                 0.93       0.640      2.37     0.609
  Insulin               10                 0.28       0.316      0.03     0.930
  CRP                   12                 −0.37      0.015      0.20     0.698

**Abbreviations:** BMI, body mass index; WHR, waist--hip ratio; WC, waist circumference; DM, diabetes mellitus; CRP, C-reactive protein.
